



# Human Anti-Human CEA (Tusamitamab) Monoclonal antibody, clone Tusamitamab (CABT-CS557)

This product is for research use only and is not intended for diagnostic use.

## PRODUCT INFORMATION

<b>Specificity</b>	CEACAM5
<b>Target</b>	CEACAM5
<b>Isotype</b>	IgG1
<b>Source/Host</b>	Human
<b>Species Reactivity</b>	Human
<b>Clone</b>	Tusamitamab
<b>Purification</b>	Protein A
<b>Conjugate</b>	unconjugated
<b>Applications</b>	ELISA
<b>Format</b>	Liquid
<b>Size</b>	1 mg
<b>Buffer</b>	PBS, pH 7.4. Contains no stabilizers or preservatives
<b>Preservative</b>	None
<b>Storage</b>	2 weeks, 2-8°C under sterile conditions after reconstitution. Avoid repeated freeze-thaw. -80°C for a long-term storage.

# BACKGROUND

## Introduction

CEA (Carcino Embryonic Antigen, CD66e) is synthesized during development in the fetal gut, and re-expressed in increased amounts in intestinal carcinomas and several other tumors. CEA is a member of carcinoembryonic antigens, immunoglobulin supergene family and consists of a single N domain (structural homology to the immunoglobulin variable) and six immunoglobulin constant-like A (A1, A2, A3) and B domains (B1, B2, B3). Antibodies to CEA are useful in identifying the origin of various metastatic adenocarcinomas and in distinguishing pulmonary adenocarcinomas (60 to 70% are CEA+) from pleural mesotheliomas (rarely or weakly CEA+).

## Keywords

CEACAM5; carcinoembryonic antigen-related cell adhesion molecule 5; CEA; CD66e